



Socioeconomic and Regional Disparities in Industry-Sponsored Clinical Trials in Multiple Sclerosis

Stefanie Marti, PhD; Andreas G. F. Hoepner, PhD; Helly Hammer, MD; Anke Salmen, MD; Andrew Chan, MD; Robert Hoepner, MD

Introduction

Addressing inequities in international industry-sponsored clinical trials of multiple sclerosis (MS) represents an unmet need. Doing so elucidates limitations in generalizability and moves toward a more inclusive process with equitable access to trials and treatments.¹

+ Supplemental content

Author affiliations and article information are listed at the end of this article.

Methods

Trial information from ClinicalTrials.gov² was combined with geographical and socioeconomic data from Natural Earth³ and human development data from the United Nations Statistics Division.⁴ Included were all phase 1 to 4 trials in MS, with the first trial in 1994 and registration through May 17, 2023, and with funder type industry, intervention type drug, study type interventional, and detailed location listing. Each location was counted as a trial site. Trials listing multiple phases were included for each phase separately. In accordance with the Common Rule, this cross-sectional study was exempt from review and informed consent because only deidentified publicly available data were used. We followed the STROBE reporting guideline.

Data processing and analyses were performed in Python 3.10 (Python Software) (eMethods in Supplement 1). The code is available on GitHub.

Results

A total of 435 phase 1 to 4 trials sponsored by 94 companies were conducted in 78 of 195 countries worldwide. Most frequent sponsors were Biogen (80 trials [18.4%]), Novartis (47 [10.8%]), Sanofi (31 [7.1%]), Hoffman-La Roche (26 [6.0%]), and GlaxoSmithKline (16 [3.7%]), financing 200 trials (46.0%). At least 1 site per continent was registered in Africa (29 trials [6.7%]); Asia (140 [32.2%]); Europe (297 [68.3%]); North America (267 [61.4%]); Australia, including Oceania region (76 [17.5%]); and South America (54 [12.4%]).

Trial sites per capita ranged from 1.2×10^{-8} in Iran to 6.7×10^{-5} in Estonia (all phases combined). Phase 2 to 3 trial sites per population were highest in the Czech Republic (phase 2) and Estonia (phase 3), whereas the largest number of phase 4 trial sites per capita was found in Germany; the world maps of the \log_{10} disproportionality of trial sites are provided in Figure 1. This \log_{10} disproportionality seemed proportional to the Human Development Index (HDI) (Figure 2).

We observed a shift from Eastern to Western Europe from phases 2 and 3 (2.1 and 1.6 times more sites, respectively, in Eastern Europe) to phase 4 (4.6 times more sites in Western Europe) (Figure 2). Most trials were conducted in countries with very high HDI (89.0% of all sites) or high HDI (10.0%), while overlooking countries with medium HDI (1.0%) and low HDI (0%).

Open Access. This is an open access article distributed under the terms of the CC-BY License.

Discussion


Multiple sclerosis, a chronic neurological disease with comparatively high medication costs, was chosen as the model disease. The findings showed inequality in trial distribution over geographical regions and socioeconomic strata, with phase 4 trials being densely conducted in countries such as Germany, France, and the US, whereas earlier phases were located in Eastern Europe and the Baltics. Virtually no trials were conducted in countries with medium or low HDI.

The study has limitations. Lower MS incidence in Africa, Asia, and South America⁵ and lower Healthcare Access and Quality Index in these regions⁶ might have affected trial feasibility. Geographical and socioeconomic data were snapshots from 2019 to 2023 and thus might not reflect the development history of countries or regions. All trial data were obtained from ClinicalTrials.gov.


We found that studies used to demonstrate the efficacy of drugs for all human beings worldwide included only a small proportion of people living in countries with high HDI. Although this practice might be partly due to difficulties in conducting trials in countries with low HDI and lower MS incidence, the regional distribution of phase 4 trials suggests commercial interests of sponsors. Safety might be compromised by adverse effects that are unlikely in countries with high HDI but

Figure 1. Disproportionality of Trial Sites

A Log₁₀ disproportionality of the actual vs expected number of phase 3 trial sites based on population




B Log₁₀ disproportionality of the actual vs expected number of phase 4 trial sites based on population



Data on industry-funded interventional drug trials for multiple sclerosis were from ClinicalTrials.gov. For each country, the expected number of trial sites was computed under the assumption that the sites were equally distributed among the world

population. Blue indicates that the actual number of sites was greater than expected, red indicates that the actual number was smaller than expected, and gray indicates no trial sites at all.

Figure 2. Distribution of Trial Sites



A-D, Data on industry-funded interventional drug trials for multiple sclerosis were from ClinicalTrials.gov, and Human Development Index (HDI) data were from the United Nations. In panel A, color changes from dark blue to light yellow represent the low to

high percentages of trials. In panels B and D, color changes from black to light red represent the low to high percentages of trial sites. Details on linear regression for panel C are provided in the eMethods in Supplement 1.

might occur in countries with low HDI, as they are virtually untested for. Excluding entire continents or socioeconomic strata from trials further exacerbates global inequities in access to treatment and introduces a bias for study interpretation on a global scale.

ARTICLE INFORMATION

Accepted for Publication: October 19, 2023.

Published: November 29, 2023. doi:10.1001/jamanetworkopen.2023.45619

Open Access: This is an open access article distributed under the terms of the CC-BY License. © 2023 Marti S et al. JAMA Network Open.

Corresponding Author: Robert Hoepner, MD, Department of Neurology, Inselspital, Bern University Hospital, University of Bern, Bern 3001, Switzerland (robert.hoepner@insel.ch).

Author Affiliations: Department of Neurology, Inselspital, Bern University Hospital, University of Bern, Bern, Switzerland (Marti, Hammer, Chan, R. Hoepner); Department of Banking and Finance, Michael Smurfit Graduate Business School, University College Dublin, Dublin, Ireland (A. G. F. Hoepner); Department of Neurology, St Josef-Hospital Bochum, Ruhr-University Bochum, Bochum, Germany (Salmen).

Author Contributions: Drs Marti and R. Hoepner had full access to all of the data in the study and takes responsibility for the integrity of the data and the accuracy of the data analysis.

Concept and design: Marti, A.G.F. Hoepner, Hammer, Salmen, R. Hoepner.

Acquisition, analysis, or interpretation of data: Marti, A.G.F. Hoepner, Salmen, Chan.

Drafting of the manuscript: Marti, R. Hoepner.

Critical review of the manuscript for important intellectual content: Marti, A.G.F. Hoepner, Hammer, Salmen, Chan.

Statistical analysis: Marti, A.G.F. Hoepner, R. Hoepner.

Administrative, technical, or material support: A.G.F. Hoepner, Hammer, Salmen, Chan, R. Hoepner.

Supervision: A.G.F. Hoepner, Salmen, R. Hoepner.

Conflict of Interest Disclosures: Dr Marti reported receiving grants from the Strategic Research Fund of the Medical Faculty of the University of Bern during the conduct of the study. Prof A.G.F. Hoepner reported receiving grants from the Strategic Research Fund of the Medical Faculty of the University of Bern during the conduct of the study; personal fees from Merck, Novartis, Roche, Biogen, Alexion, Sanofi, Janssen, Bristol-Myers Squibb, Teva/Mepha, and Almirall; research support from Roche, Merck, Sanofi, Biogen, Chiesi, and Bristol-Myers Squibb; and grants from the Swiss Multiple Sclerosis (MS) Society and Sitem-Insel Support Funds and being a member of the Advisory Board of the Swiss and International MS Society and the deputy editor in chief of *Journal of Central Nervous System Disease* outside of the submitted work. Dr Salmen reported receiving personal fees from Bristol Myers Squibb, CSL Behring, Novartis, and Roche and institutional grants from Baasch Medicus Foundation, the Medical Faculty of the University of Bern, and the Swiss MS Society outside the submitted work. Prof Chan reported receiving grants from UCB, Roche, Biogen, CSL Behring, and Genzyme and personal fees from Janssen, Alexion, Allmirall, Biogen, Bristol Myers Squibb, Merck, Genzyme, Novartis, Roche, Teva, and Horizon outside the submitted work. No other disclosures were reported.

Funding/Support: This study was funded by the Strategic Research Fund of the Medical Faculty of the University of Bern, Bern, Switzerland.

Role of the Funder/Sponsor: The funder had no role in the design and conduct of the study; collection, management, analysis, and interpretation of the data; preparation, review, or approval of the manuscript; and decision to submit the manuscript for publication.

Data Sharing Statement: See [Supplement 2](#).

REFERENCES

1. US Department of Health & Human Services, National Institutes of Health. Diversity and inclusion in clinical trials. April 24, 2023. Accessed August 8, 2023. <https://www.nimhd.nih.gov/resources/understanding-health-disparities/diversity-and-inclusion-in-clinical-trials.html>
2. ClinicalTrials.gov. Version v2.1.1. National Library of Medicine. Accessed May 17, 2023. <https://beta.clinicaltrials.gov/>
3. Natural Earth. Accessed August 8, 2023. <https://www.naturalearthdata.com/>
4. United Nations Statistics Division. Accessed August 8, 2023. <https://unstats.un.org/UNSDWebsite/>
5. GBD 2016 Multiple Sclerosis Collaborators. Global, regional, and national burden of multiple sclerosis 1990-2016: a systematic analysis for the Global Burden of Disease Study 2016. *Lancet Neurol*. 2019;18(3):269-285. doi:10.1016/S1474-4422(18)30443-5
6. GBD 2015 Healthcare Access and Quality Collaborators. Healthcare Access and Quality Index based on mortality from causes amenable to personal health care in 195 countries and territories, 1990-2015: a novel analysis from the Global Burden of Disease Study 2015. *Lancet*. 2017;390(10091):231-266. doi:10.1016/S0140-6736(17)30818-8

SUPPLEMENT 1.

eMethods.

eReferences

SUPPLEMENT 2.

Data Sharing Statement